$2.3bn Pfizer settlement strips legal team of compliance brief

Pfizer general counsel will no longer oversee its compliance programme under the terms of the $2.3bn (£1.4bn) settlement resolving allegations of illegal marketing of painkiller Bextra and several other drugs, writes Corporate Counsel.

Pfizer general counsel will no longer oversee its compliance programme under the terms of the $2.3bn (£1.4bn) settlement resolving allegations of illegal marketing of painkiller Bextra and several other drugs, writes Corporate Counsel.

Instead, the chief compliance officer at the world’s largest drug maker will report directly to the chief executive. The move is required by Pfizer’s corporate integrity agreement with the office of the inspector general of the US Department of Health and Human Services  (HHS), part of the company’s civil and criminal settlement with the Department of Justice.

This premium content is reserved for
Legal Week Subscribers.

Subscribe today to get ALL ACCESS and 15% off!

A premium subscription gives you access to all articles and provides:

  • Trusted insight, news and analysis from the UK and across the globe
  • Connections to senior business lawyers within the leading law firms and legal departments
  • Unique access to ALM’s unrivalled, market-leading reporting in the US and Asia and cutting-edge research, including Legal Week’s UK Top 50 and Global 100 rankings
  • The Legal Week Daily News Alert, Editor’s Highlights, and Breaking News digital newsletters and more, plus a choice of over 70 ALM newsletters
  • Optimized access on all of your devices: desktop, tablet and mobile
  • Complete access to the site’s full archive of more than 56,000 articles

Subscribe Now For All Access

For enterprise-wide or corporate enquiries, please contact Paul Reeves on Preeves@alm.com or call on +44 (0) 203 875 0651